OrbiMed’s Seagen Inc. Common Stock SGEN Stock Holding History

OrbiMed’s Portfolio SGEN Stock Details SGEN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-50,000	Closed	-$10.6M	–	139
2023 Q3	$10.6M	Buy	+50,000	New	+$9.99M	0.23%	82
2022 Q4	–	Sell	-25,000	Closed	-$3.42K	–	134
2022 Q3	$3.42K	Sell	25,000 -25,000	-50%	-$4.07M	0.06%	111
2022 Q2	$8.85K	Buy	+50,000	New	+$7.21M	0.16%	97
2013 Q3	–	Sell	-200,000	Closed	-$6.29M	–	137
2013 Q2	$6.29M	Buy	+200,000	New	+$6.98M	0.13%	94

Other funds holding SGEN

SCM

Segantii Capital Management Hong Kong $1.54B AUM 16.73% 1-Year Est. Return

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

FBC

Fairfield, Bush & Co Darien, Connecticut $180M AUM 39.51% 1-Year Est. Return

VWA

Valued Wealth Advisors Holladay, Utah $247M AUM 21.93% 1-Year Est. Return

SAG

Spotlight Asset Group Oakbrook Terrace, Illinois $143M AUM 20.66% 1-Year Est. Return

OrbiMed's SGEN Position: Q4 2023 in Review

OrbiMed sold out of Seagen Inc. Common Stock (SGEN) in Q4 2023, closing a stake of 42,600 shares — an estimated $9.04M sold.

OrbiMed first reported a position in SGEN in Q3 2021 and held it in 7 quarters. The position peaked at $117M in Q4 2022. 6 funds tracked by Wall St. Rank hold SGEN as of Q4 2023.

OrbiMed reported no remaining Seagen Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
OrbiMed sold 42,600 Seagen Inc. Common Stock shares in Q4 2023, an estimated $9.04M.
OrbiMed first reported a position in Seagen Inc. Common Stock in Q3 2021 and held it in 7 quarters.
OrbiMed's Seagen Inc. Common Stock position peaked at $117M in Q4 2022.
6 funds tracked by Wall St. Rank held Seagen Inc. Common Stock as of Q4 2023.

Based on OrbiMed's 13F filing for Q4 2023, filed 14 Feb 2024.